IMAGE study: Isatuximab plus pomalidomide and dexamethasone for RRMM in the real-world setting

The Multiple Myeloma Hub is pleased to present a visual abstract of a retrospective study by Decaux et al.¹ which evaluated real-world outcomes following at least one dose of isatuximab in combination with pomalidomide and dexamethasone (Isa-Pd) for the treatment of relapsed/refractory multiple myeloma (RRMM). The data from these patients were separated by subgroups based on prior lines of therapy as well as refractoriness to lenalidomide and daratumumab.¹

The key findings from this study are as follows¹:

• A median progression-free survival (PFS) of 12.4 months was observed following treatment with Isa-Pd in the real-world population, comparable to results from clinical trials, including ICARIA-MM (NCT02990338) and APOLLO (NCT03180736).
• Isa-Pd showed a PFS benefit when used as a second-line treatment in patients who were exposed to, but not refractory to, daratumumab, as well as in patients who were refractory to lenalidomide.
• The median PFS for patients refractory to daratumumab was the lowest among all subgroups, at 3.0 months, highlighting the challenges of treating this population.
• The overall response rate (ORR) in the study was 46.3%, with 27.9% of patients experiencing a very good partial response (VGPR).
• Response rates were largely consistent across subgroups, demonstrating the efficacy of Isa-Pd, regardless of prior therapies or refractory status.
• These data align with results from randomized controlled trials, providing further support for the use of Isa-Pd in real-world settings. 
• Permanent treatment discontinuation due to toxicity was rare, occurring in 1.3% of patients.
• The safety profile of Isa-Pd was considered manageable, with no new safety concerns identified compared with prior clinical trials.

 This educational resource is independently supported by Sanofi. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.